Evidence map›Paper›PMID 38691679›Full record

Trial reportBlood2024

Impact of hematopoietic cell transplantation on myocardial fibrosis in young patients with sickle cell disease.

Akshay Sharma, Subodh Selukar, Yu Bi, Anthony Merlocco, Cara E Morin, Chris Goode, Parul Rai, Jeffrey A Towbin, Jane S Hankins, Stephen Gottschalk and 2 more

Registry-linked trialOpen access · greenAbstract readClinical Trial
In one paragraph

Trial report in Blood, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04362293 (Reduced Intensity Related Donor Peripheral Blood Derived Hematopoietic Progenitor Cell Transplantation for Patients With Severe Sickle Cell Disease), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04362293 phase2suspendednot on this map

Reduced Intensity Related Donor Peripheral Blood Derived Hematopoietic Progenitor Cell Transplantation for Patients With Severe Sickle Cell Disease

TypeinterventionalSponsorSt. Jude Children's Research HospitalRan2020 to 2029Enrolled40ConditionsSickle Cell DiseaseArmshydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus, hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Akshay SharmaDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0003-3281-2081
Subodh SelukarDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0002-3802-488X
Yu BiDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0009-0001-6484-2034
Anthony MerloccoDivision of Pediatric Cardiology, The University of Tennessee Health Science Center, Memphis, TN.ORCID 0000-0001-6228-0229
Cara E MorinDepartment of Pediatric Radiology, Cincinnati Children's Hospital, Cincinnati, OH.ORCID 0000-0003-1953-4486
Chris GoodeDepartment of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN.
Parul RaiDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0002-5770-7280
Jeffrey A TowbinDivision of Pediatric Cardiology, The University of Tennessee Health Science Center, Memphis, TN.
Jane S HankinsDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0003-4439-7321
Stephen GottschalkDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0003-3991-7468
Brandon TriplettDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-8220-9980
Jason N JohnsonDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0003-0712-1123
St. Jude Children's Research Hospital · USCincinnati Children's Hospital Medical Center · USUniversity of Tennessee Health Science Center · US

Funding

Novel therapeutic gene editing to induce fetal hemoglobin for sickle cell diseaseU01HL163983 · NHLBI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Akshay Sharma, Shengdar Tsai · 2023 to 2026
$4.9M
NHLBI NIH HHS U01 HL163983
6 · The paper itself

Abstract

abstractSerial cardiovascular magnetic resonance evaluation of children and young adults with SCD who underwent hematopoietic cell transplantation showed mean ECV, representing diffuse myocardial fibrosis, decreased 3.4% from baseline to 12 months posttransplantation. This trial was registered at www.clinicaltrials.gov as #NCT04362293.

Indexed as

Anemia, Sickle CellHematopoietic Stem Cell TransplantationMyocardiumAdolescentAdultCardiomyopathiesChildChild, PreschoolFemaleFibrosisHumansMagnetic Resonance ImagingMaleYoung Adult

Identifiers

PMID38691679
PMCPMC11347799
OpenAlexW4396562385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.